G. Kremenopoulos et al., THE BEST TIMING OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ADMINISTRATION INANEMIA OF PREMATURITY - A RANDOMIZED CONTROLLED-STUDY, International journal of pediatric hematology/oncology, 4(4), 1997, pp. 373-383
Recombinant human erythropoietin (rHuEPO) treatment successfully preve
nts anemia of prematurity during the period when it is administered. H
owever, data on the duration and optimal timing of rHuEPO administrati
on are unavailable. A total of 85 neonates with birth weight less than
or equal to 1500 g, gestational age less than or equal to 31 weeks we
re entered in a controlled study of rHuEPO administration. Of these, 5
0 neonates (group A) were randomly assigned to take rHuEPO (3 x 250 U/
kg/wk subcutaneously) (n = 24) or no rHuEPO (control n = 26), early af
ter birth (3 to 7 days) for 6 weeks. Retrospectively, these neonates w
ere classified into those without (n = 22) and with complications (n =
28) (mechanical ventilation If: sepsis). Subsequently 35 neonates (gr
oup B) were randomly assigned to take rHuEPO (3 x 200 U/kg/wk subcutan
eously) (n = 20) or no rHuEPO (control n = 15) after their problems ha
d been resolved and when they were receiving full enteral feeding. Hem
atologic parameters, transfusion requirements and growth were followed
during the entire hospitalization period. Reticulocyte counts during
rHuEPO treatment were significantly higher in all rHuEPO recipients co
mpared with their controls. Regarding transfusions, infants with compl
ications did not benefit from rHuEPO administration [erythropoietin (E
PO) neonates: 5 +/- 2.5, control neonates: 4.9 +/- 1.4] whereas both n
eonates without complications in group A (EPO neonates: 0.2 +/- 0.4, c
ontrol neonates: 1 +/- 0.7) and neonates in group B (EPO neonates: 0.4
+/- 0.9, control neonates: 1.8 +/- 1.3) received significantly fewer
blood transfusions during rHuEPO administration. In conclusion rHuEPO
should be administered only in neonates without complications or when
complications have been resolved and full enteral feeding has been est
ablished. We suggest that rHuEPO therapy should be given until neonate
s ape discharged from the hospital.